Criteria to qualify for study: Drug used in study:
  • First line treatment
  • Low blast count

MDS 21
Phase 3, Randomized, Controlled, Open label, Clinical Study of Pevonedistat Plus Azacitidine versus single agent Azacitidine as First-Line treatment for patients with higher risk Myelodysplatic Syndrome, Chronic Myelomonocytic Leukemia, of Low Blast Acute Myelogenous Leukemia.